Jennifer A. Baird, President and CEO,
Accuri Cytometers, Inc. has led teams of technology developers, process
improvement and sales/marketing groups generating significant cost
savings, new products and sales for her clients and employers. As a Vice President at Keane Consulting Group she helped build the company as it quintupled in size to over 150 staff and managed over $10M in projects. At
ISSYS Sensing Systems, Inc (MI), Ms. Baird led fundraising, marketing/sales,
business development, grant proposal writing, public relations, regulatory
affairs, human resources, and product development.
Ms. Baird holds a BA in Organizational Psychology from the University of Michigan and an MBA from Kellogg Graduate School of Management, where she shared Top-of-Class honors.
Daniel
J. Calvo, President and CEO, Assay Designs, Inc. has
more than 25 years experience in life and health sciences. Most
recently, he was CEO of Cellomics, Inc., the leader in the High
Content Screening market, which was acquired by Fisher Scientific
International Prior to that, Dan was VP, Worldwide Sales
and Service at PerkinElmer Life and Analytical Sciences, a leading
global provider of instruments, reagents, software and services
for the life sciences, drug discovery and diagnostics markets.
In his role at Perkin Elmer, Dan led the integration and expansion
of PerkinElmer’Äôs life science business, growing from $200 million
to $500 million. Dan was Senior VP, Global Sales and Marketing
for NEN Life Sciences, where he drove a significant turnaround
of the company prior to the acquisition by PerkinElmer. He spent
more than 15 years at DuPont in various sales, marketing and
operational assignments in their Medical Products business.
Dan received an AB degree in biochemistry from Princeton University,
an MHS in Environmental Health Engineering from The Johns Hopkins
University and an MBA in Business Administration from Bellarmine
College.
George W. Dunbar, President and Chief Executive
Officer, Aastrom Biosciences, Inc. and a member of Aastrom’Äôs Board
of Directors, has more than thirty years of experience in
the healthcare field, including the biotech, pharmaceutical, diagnostic
and device sectors. During this period, he has spent more than
fifteen years as a chief executive officer of established and early-stage
lifesciences companies. Most recently he was the Chief Executive
Officer of Quantum Dot Corporation. Prior to that, he was Chief
Executive Officer of Targesome, Inc. George also served as
Chief Executive Office of Epic Therapeutics. Prior to that, he
served at various times as Chief Executive Officer of Cytotherapeutics,
Stem Cells, Inc. and Metra Biosystems, and in management positions
with the Ares-Serono Group and Amersham International.
George received
a B.S. in Electrical Engineering and an MBA from Auburn University.
He currently serves on the board of directors of Sonus Pharmaceuticals
as well as on the MBA Advisory Board of the Auburn University College
of Business.
Thomas C. Kinnear, PhD., Professor
of Entrepreneurial Studies at the University of Michigan and Executive
Director, Samuel Zell and Robert H. Lurie Institute for Entrepreneurial
Studies, Professor Kinnear is a recognized expert in marketing
management and research, and is a Director and Vice Chair of the
American Marketing Association Foundation. He is active in
the entrepreneurial community as a co-founder, advisor, equity
investor and a limited partner in four Michigan-based venture funds. He distinguished himself as the University of Michigan's former Vice President of Development and the Business School's D. Maynard Phelps Professor of Marketing. In 1997, he was awarded the Eugene Applebaum Professorship of Entrepreneurial Studies.
Professor Kinnear holds a Ph.D. from the University of Michigan, an MBA from Harvard Business School, and a bachelor's degree from Queens College.
Tim Petersen, Managing Director, Arboretum Ventures, in 2002, joined partner Jan Garfinkle in launching Arboretum Ventures. Tim serves on the Board of Directors of Advanced ICU Care, HealthMedia, and KFx Medical, four of Arboretum’s portfolio investments, and previously sat on the Board of Asterand (LSE: ATD). Immediately prior to Arboretum, Tim was the Managing Director of the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan. He also directed the activities of the Wolverine Venture Fund, an evergreen fund that includes the active participation of Michigan’s MBA students. Previously, Tim spent nine years at Industrial Economics, Inc., becoming a member of the firm’s senior management team in 1991. Industrial Economics, founded in the early 1980’s in Cambridge, MA, is a leader in the fields of natural resource economics and environmental science.
Tim holds a BA in Economics from Williams College, an MS in Economics from the University of Wisconsin, and an MBA from the University of Michigan. Tim serves on a number of advisory boards, including the Michigan Universities Commercialization Initiative and the Biogenerator (St. Louis).
Peter K. Shagory, Partner, Baird Venture Partners, oversees the healthcare and life sciences investment effort for BVP. Prior to joining Baird Venture Partners in 2004, Pete spent five years at Vector Fund Management, L.P., a life-sciences venture capital firm, investing broadly across the medical device and biotechnology fields. Prior to Vector, he spent over six years in corporate finance, mergers & acquisitions and merchant banking at J.P. Morgan & Co. and Banc One Capital Corporation. Pete is currently a member of the Board of Directors of NimbleGen Systems, Inc., Arbor Surgical Technologies, Inc., PharMEDium Healthcare Corporation, and Caden Biosciences, Inc., and is involved with CoAxia, Inc. and Aptus Endosystems, Inc.
Pete received his undergraduate degree in Business Administration and Finance from Miami University in Oxford, Ohio and his MBA from the Amos Tuck School at Dartmouth College.
